Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Skye Bioscience, Inc. (Nasdaq: SKYE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Skye is a Nevada corporation and clinical-stage biotechnology company focused on metabolic health, and its filings offer structured insight into its financial condition, clinical programs, and material corporate events.
Investors researching SKYE can use this page to review current and historical reports such as Form 8-K, where Skye has furnished press releases on topics including topline CBeyond™ Phase 2a data for nimacimab, financial results for specific reporting periods, and other corporate updates. These 8-K filings link clinical milestones—such as Phase 2a obesity trial readouts, extension study enrollment, and Phase 1b results in metabolic-associated steatotic liver disease—to the company’s formal disclosure record.
Through Stock Titan, Skye’s filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents, allowing users to quickly understand the context of complex clinical and financial information. This includes highlighting how Skye describes nimacimab’s development status, safety and efficacy data reported in furnished press releases, and the company’s stated plans for future clinical studies.
In addition to event-driven Form 8-Ks, users can locate Skye’s annual and quarterly reports, once available, to examine consolidated financial statements, research and development expenditures, and risk factor discussions related to its obesity and metabolic health programs. The filings page also provides a path to monitor any future ownership and insider transaction disclosures, such as Form 4 filings, when they are reported. Together, these documents form a detailed regulatory history that supports deeper analysis of SKYE as a clinical-stage biotech issuer.
Skye Bioscience announced that Chief Financial Officer Kaitlyn Arsenault will step down effective February 20, 2026 to pursue new professional opportunities and will continue as an advisor. Under a Separation and Release Agreement, she will receive a $450,000 cash severance, an additional $45,000 toward her 2026 annual bonus, reimbursement of up to $30,000 in legal fees, and a lump-sum payment of $41,172.48 equal to 12 months of COBRA premiums.
Certain outstanding equity awards will continue to vest during her advisory term, and unvested awards will fully vest if a Change in Control occurs within a year and before the advisory role ends. Vested stock options will remain exercisable until the later of February 20, 2027 or 90 days after the advisory term ends. The company states her departure is not due to any disagreement on financial reporting or company practices. In connection with this change, the Board appointed CEO Punit Dhillon as principal accounting officer, with his existing compensation and roles otherwise unchanged.
Skye Bioscience director receives stock option grant. Director Andrew J. Schwab was granted a stock option for 35,000 shares of Skye Bioscience, Inc. common stock on February 6, 2026. The option has an exercise price of $0.82 per share and was awarded at no cost to him.
The option vests in equal monthly installments over a one-year period beginning January 19, 2026, and is exercisable until February 6, 2036. Following this grant, Schwab holds 35,000 derivative securities directly in the form of this stock option.
Skye Bioscience director Grayson Paul A. received a grant of stock options on February 6, 2026. The award covers 35,000 stock options to buy Skye Bioscience common stock at an exercise price of $0.82 per share, held as a direct ownership position.
According to the footnote, the option vests in equal monthly installments over a one-year period beginning January 19, 2026. After this transaction, the director beneficially holds 35,000 derivative securities related to Skye Bioscience common stock.
Skye Bioscience director Karen L. Smith reported receiving a stock option award. On 02/06/2026 she was granted an option to buy 35,000 shares of common stock at an exercise price of $0.82 per share. The option vests in equal monthly installments over the one-year period beginning January 19, 2026, and all 35,000 derivative securities are held directly.
Skye Bioscience reported that its Chief Financial Officer, Kaitlyn Arsenault, received a grant of stock options on February 6, 2026. The award covers 125,000 options to buy common stock at an exercise price of $0.82 per share. The options vest in equal monthly installments over a four-year period beginning January 19, 2026, aligning her long-term compensation with the company’s share performance.
Skye Bioscience Chief Scientific Officer granted 150,000 stock options. Christopher Twitty received a stock option for 150,000 shares of common stock at an exercise price of $0.82 per share on February 6, 2026. All 150,000 options are held directly.
The option vests in equal monthly installments over a four-year period beginning January 19, 2026, meaning portions become exercisable each month over that timeframe rather than all at once.
Skye Bioscience director Deborah H. Charych received stock options for 35,000 shares of common stock. The options have an exercise price of $0.82 per share and were granted on February 6, 2026. They vest in equal monthly installments over a one-year period beginning January 19, 2026, and expire on February 6, 2036.
Skye Bioscience director Annalisa Jenkins received a grant of stock options covering 35,000 shares of common stock on February 6, 2026. The options have an exercise price of $0.82 per share and expire on February 6, 2036.
According to the filing, the option vests in equal monthly installments over a one-year period beginning January 19, 2026. After this grant, Jenkins beneficially owns 35,000 stock options, held directly.
Skye Bioscience Chief Development Officer granted 125,000 options to buy common stock at an exercise price of $0.82 per share. The award was made on February 6, 2026 and expires on February 6, 2036.
The stock option vests in equal monthly installments over four years beginning January 19, 2026, meaning the officer earns the right to exercise more of the grant every month during that period, as long as service conditions are met.
Skye Bioscience Chief Medical Officer granted stock options. On February 6, 2026, Chief Medical Officer Puneet S. Arora received a stock option to buy 125,000 shares of Skye Bioscience common stock at an exercise price of $0.82 per share. The option vests in equal monthly installments over four years beginning January 19, 2026, and is held directly by the reporting person.